Associations - Leiomyosarcoma

No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	trabectedin Sensitive: A1 - Approval	trabectedin Sensitive: A1 - Approval
No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: A2 - Guideline	eribulin mesylate Sensitive: A2 - Guideline
No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	No biomarker No biomarker	Leiomyosarcoma Leiomyosarcoma	PTC596 Sensitive: B - Late Trials	PTC596 Sensitive: B - Late Trials
Chr amplification(4)(q22.1) Chr amplification(4)(q22.1)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(4)(q22.1) Chr amplification(4)(q22.1)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr del(3)(q14.2) Chr del(3)(q14.2)	Leiomyosarcoma Leiomyosarcoma	Chr del(3)(q14.2) Chr del(3)(q14.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr del(11)(q25) Chr del(11)(q25)	Leiomyosarcoma Leiomyosarcoma	Chr del(11)(q25) Chr del(11)(q25)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr del(2)(q14.1) Chr del(2)(q14.1)	Leiomyosarcoma Leiomyosarcoma	Chr del(2)(q14.1) Chr del(2)(q14.1)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr del(2)(p12) Chr del(2)(p12)	Leiomyosarcoma Leiomyosarcoma	Chr del(2)(p12) Chr del(2)(p12)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials	eribulin mesylate Sensitive: C3 – Early Trials
Chr del(1)(q44) Chr del(1)(q44)	Leiomyosarcoma Leiomyosarcoma	Chr del(1)(q44) Chr del(1)(q44)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr amplification(8)(q13.2) Chr amplification(8)(q13.2)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(8)(q13.2) Chr amplification(8)(q13.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr amplification(8)(q22.2) Chr amplification(8)(q22.2)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(8)(q22.2) Chr amplification(8)(q22.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr amplification(13)(q13.3) Chr amplification(13)(q13.3)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(13)(q13.3) Chr amplification(13)(q13.3)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr amplification(20)(p12.2) Chr amplification(20)(p12.2)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(20)(p12.2) Chr amplification(20)(p12.2)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
Chr amplification(4)(q26) Chr amplification(4)(q26)	Leiomyosarcoma Leiomyosarcoma	Chr amplification(4)(q26) Chr amplification(4)(q26)	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Resistant: C3 – Early Trials	eribulin mesylate Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	eribulin mesylate Sensitive: C3 – Early Trials	eribulin mesylate Sensitive: C3 – Early Trials
ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	ATRX mutation ATRX mutation	Leiomyosarcoma Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials	dacarbazine Resistant: C3 – Early Trials
TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	dacarbazine Resistant: C3 – Early Trials	dacarbazine Resistant: C3 – Early Trials
AKT1 mutation + mTOR mutation AKT1 mutation + mTOR mutation	Leiomyosarcoma Leiomyosarcoma	AKT1 mutation + mTOR mutation AKT1 mutation + mTOR mutation	Leiomyosarcoma Leiomyosarcoma	CB-228 Sensitive: C3 – Early Trials	CB-228 Sensitive: C3 – Early Trials
TMB-H TMB-H	Leiomyosarcoma Leiomyosarcoma	TMB-H TMB-H	Leiomyosarcoma Leiomyosarcoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
MYH9-ALK + ALK-WDR43 MYH9-ALK + ALK-WDR43	Leiomyosarcoma Leiomyosarcoma	MYH9-ALK + ALK-WDR43 MYH9-ALK + ALK-WDR43	Leiomyosarcoma Leiomyosarcoma	crizotinib Sensitive: C4 – Case Studies	crizotinib Sensitive: C4 – Case Studies
PTEN mutation + TSC1 mutation PTEN mutation + TSC1 mutation	Leiomyosarcoma Leiomyosarcoma	PTEN mutation + TSC1 mutation PTEN mutation + TSC1 mutation	Leiomyosarcoma Leiomyosarcoma	CB-228 Sensitive: C4 – Case Studies	CB-228 Sensitive: C4 – Case Studies
NF1 mutation NF1 mutation	Leiomyosarcoma Leiomyosarcoma	NF1 mutation NF1 mutation	Leiomyosarcoma Leiomyosarcoma	IPN60090 Sensitive: C4 – Case Studies	IPN60090 Sensitive: C4 – Case Studies
YWHAE-JAZF1 fusion YWHAE-JAZF1 fusion	Leiomyosarcoma Leiomyosarcoma	YWHAE-JAZF1 fusion YWHAE-JAZF1 fusion	Leiomyosarcoma Leiomyosarcoma	regorafenib Sensitive: C4 – Case Studies	regorafenib Sensitive: C4 – Case Studies
PLK4 expression PLK4 expression	Leiomyosarcoma Leiomyosarcoma	PLK4 expression PLK4 expression	Leiomyosarcoma Leiomyosarcoma	CFI-400945 Sensitive: D – Preclinical	CFI-400945 Sensitive: D – Preclinical
CSPG4 overexpression CSPG4 overexpression	Leiomyosarcoma Leiomyosarcoma	CSPG4 overexpression CSPG4 overexpression	Leiomyosarcoma Leiomyosarcoma	CSPG4.TNK Sensitive: D – Preclinical	CSPG4.TNK Sensitive: D – Preclinical
HAT1 overexpression HAT1 overexpression	Leiomyosarcoma Leiomyosarcoma	HAT1 overexpression HAT1 overexpression	Leiomyosarcoma Leiomyosarcoma	pazopanib Resistant: D – Preclinical	pazopanib Resistant: D – Preclinical
MAN1A1-ROS1 rearrangement MAN1A1-ROS1 rearrangement	Leiomyosarcoma Leiomyosarcoma	MAN1A1-ROS1 rearrangement MAN1A1-ROS1 rearrangement	Leiomyosarcoma Leiomyosarcoma	crizotinib Sensitive: D – Preclinical	crizotinib Sensitive: D – Preclinical
TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	TP53 mutation TP53 mutation	Leiomyosarcoma Leiomyosarcoma	selinexor + eribulin mesylate Sensitive: D – Preclinical	selinexor + eribulin mesylate Sensitive: D – Preclinical

Leiomyosarcoma

Associations(30)

Associations
(30)